


Docket No. 033393/055194

**PATENT**



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In application of: LIERBERMAN, Judy; SHANKAR, Premrata; NARASIMHASWAMY, Manjunath; SONG, Erwei; LEE, Sang-Kyung; INCE, Nedim

Application No.: 10/533,622      Group No.: Not yet assigned  
 Filed: April 29, 2005      Examiner: Not yet assigned  
 For: METHODS FOR TREATING AND PREVENTING APOPTOSIS-RELATED DISEASES USING RNA INTERFERING AGENTS

**MAIL STOP AMENDMENT**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a))**


I hereby certify that the attached correspondence comprising:

1. Certificate of Mailing (1 page);
2. Transmittal Form (1 page);
3. Information Disclosure Statement with Form 1449 (3 pages);
4. COPY – References C1-C11;
5. COPY – Limited Recognition Statement (1 pg); and
6. Return Receipt Postcard.

is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

**MAIL STOP AMENDMENT**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

Date: 9/13/05

  
 Signature

**CATHERINE KEARNS**

(type or print name of person certifying)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/533,622
Filing Date	April 29, 2005
First Named Inventor	Judy Lieberman
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	033393/055194

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Certificate of Mailing; Information Disclosure Statement with Form 1449; COPY - References C1-C11; Limited Recognition Statement; and Return Receipt Postcard
<b>Remarks</b> The Commissioner is authorized to charge fee deficiencies or credit overpayments to the NIXON PEABODY LLP Deposit Account No. 50-0850.		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	NIXON PEABODY LLP		
Signature			
Printed name	David S. Resnick/Leena H. Karttunen		
Date	9/13/2005	Reg. No.	34,235/L0207

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	CATHERINE KEARNS	Date	9/13/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATES PATENT AND TRADEMARK OFFICE**

**LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)**

Leena H. Karttunen is hereby given limited recognition under 37 CFR § 11.9(b), as an employee of the law firm of Nixon Peabody LLP, to prepare and prosecute patent applications wherein the patent applicant is a client of the law firm of Nixon Peabody LLP, and a registered practitioner, who is a member of the law firm of Nixon Peabody LLP, is the practitioner of record in the applications. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Leena H. Karttunen ceases to lawfully reside in the United States, (ii) Leena H. Karttunen's employment with the law firm of Nixon Peabody LLP, ceases or is terminated, or (iii) Leena H. Karttunen ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such limited recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Limited Recognition No. L0207  
Expires: September 30, 2005



Harry I. Moatz  
Director of Enrollment and Discipline

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: LIEBERMAN, Judy; SHANKAR, Premata; NARASIMHASWAMY, Manjunath;  
SONG, Erwei; LEE, Sang-Kyung; INCE, Nedim

Application No.: 10/533,622  
Filed: April 29, 2005

Group No.: To be assigned  
Examiner: To be assigned

For: METHODS FOR TREATING AND PREVENTING APOPTOSIS-RELATED  
DISEASES USING RNA INTERFERING AGENTS

CERTIFICATE OF MAILING

I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage in an envelope addressed to Mail Stop Amendment, Commissioner of Patents, Box 1450, Alexandria, VA 22313-1450.

Date: 9/13/05

CATHERINE KEARNS

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

I. REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- X   (1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or
- (2) within three months of the mailing date of the PCT International Search Report; or

- (3) after the period defined in (1) but before the mailing date of a **Final Rejection** or **Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$180.00**, is included herein; or
- (4) after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

— A copy of the International Search Report is enclosed herewith.

It is respectfully requested that each of the documents shown on the attached form(s) 1449/A/B/PTO be made of record in this application.

Copies of these documents (CHECK ONE):

  X   are enclosed herewith that have not been previously submitted; or

— have been cited in the parent application, and are thus not being resubmitted herein.

#### FEE AUTHORIZATION

The Commissioner is authorized to charge fee deficiencies or credit overpayments associated with this submission to the NIXON PEABODY LLP Deposit Account No. 50-0850.

Date: 9/13/05

Customer No. 50828

Respectfully submitted,



David S. Resnick (Reg. 34,235)  
Leena H. Karttunen (L0207)  
NIXON PEABODY LLP  
100 Summer Street  
Boston, MA 02110-2131  
(617) 345-6057

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449 PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/533,622
				Filing Date	April 29, 2005
				First Named Inventor	Judy Lieberman
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	1	Attorney Docket Number	033393/55194

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> (if known)			

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	ASHKENAZI, A. and DIXIT, V.M. Death receptors: signaling and modulation (1998) <i>Science</i> 281:1305-1308.
	C2	GREEN, D.R. and EVANS, G.I. A matter of life and death (2002) <i>Cancer Cell</i> 1:19-30.
	C3	MATTSON, M.P. Apoptosis in neurodegenerative disorders (2002) <i>Nat. Rev. Mol. Cell. Biol.</i> 1:120-128.
	C4	MEIER, P., et al. Apoptosis in development (2000) <i>Nature</i> 407:796-801.
	C5	NANSEN et al. The role of CC chemokine receptor 5 in antiviral immunity (2002) <i>Blood</i> 99:1237-1245.
	C6	RATHMELL, J.C. and THOMPSON, C.B. Pathways of apoptosis in lymphocyte development, homeostasis, and disease (2002) <i>Cell</i> 109 (Suppl.): S97-S107.
	C7	ROWE, P.M., Glimmers of clinical relevance for Fas (1996) <i>Lancet</i> , 347: 1398
	C8	VAUX, D.L. and KORSMEYER, S.J. Cell death in development (1999) <i>Cell</i> 96:245-254.
	C9	VERMUELEN, K., et al. Cell cycle and apoptosis (2003) <i>Cell Prolif.</i> 36:165-175.
	C10	WATANABE-FUKUNAGA, R., et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen (1992) <i>J. Immunol.</i> , 148:1274-1279
	C11	ZÖRNIG, M., et al. Apoptosis regulators and their role in tumorigenesis (2001) <i>Biochim. Biophys. Acta</i> 1551:F1-F37.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.